Search
Suprofen
go.drugbank.com/drugs/DB00870ApprovedWithdrawnIt inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. It is no longer approved for use in the United States.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InhibitorsTroleandomycin
go.drugbank.com/drugs/DB13179ApprovedA macrolide antibiotic that is similar to erythromycin.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsGefapixant
go.drugbank.com/drugs/DB15097ApprovedIt has been estimated that 5-10% of adults globally suffer from chronic cough, which is defined as a cough lasting longer than eight weeks. … [L48596] Existing treatments for chronic cough have been associated with considerable side effects, in particular opioids such as [codeine] or [dextromethorphan].
Idelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalBy inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and … Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesSynonyms: 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one, 5-fluoro-3-phenyl-2-[(1S)-1-(3H-purin-6-ylamino)propyl]quinazolin-4(3H)-onePrasterone
go.drugbank.com/drugs/DB01708ApprovedInvestigationalNutraceuticalIn November 2016, DHEA was approved (as Intrarosa) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause … DHEA and DHEAS are readily available in the United States, where they are marketed as over-the-counter dietary supplements.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: 3β-hydroxyandrost-5-en-17-one, 3-beta-hydroxy-5-androsten-17-oneTopiroxostat
go.drugbank.com/drugs/DB01685InvestigationalRenal complications are major comorbidities that limit the [DB00437] therapy as dose reductions are recommended. … Xanthine oxidase inhibitors are classified into two groups; purine analogs such as [DB00437] and [DB05262], and non-purine agents which includes topiroxostat.
Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C8 InhibitorsSynonyms: 4-(5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl)pyridine-2-carbonitrilePropoxycaine
go.drugbank.com/drugs/DB09342ApprovedThis drug was removed from the US market in 1996. … Used in combination with procaine, it was the only dental local anesthetic available in cartridge form [L1592].
Bexotegrast
go.drugbank.com/drugs/DB16515InvestigationalThe compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical … Phase 2a studies are currently evaluating PLN-74809 safety and efficacy for participants with IPF (NCT04396756)across 10 participating countries[L31703], and for participants with PSC (NCT04480840).
Enoxolone
go.drugbank.com/drugs/DB13089InvestigationalEnoxolone (glycyrrhetic acid) has been investigated for the basic science of Apparent Mineralocorticoid Excess (AME).
Mixtures: ANZİBEL 5 MG/4 MG/3 MG EKİNEZYALI PASTİL, 20 ADET, ANZİBEL 5 MG/4 MG/3 MG MEYANBALLI PASTİL, 20 ADETGALE-301
go.drugbank.com/drugs/DB17262InvestigationalIt is made up of E39, an immunogenic peptide derived from the folate binding protein (FBP), and an immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF).[A254696,L44166,L44171]